Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why Edge Therapeutics Stock Collapsed Today

By Maxx Chatsko - Mar 28, 2018 at 12:53PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biopharma's shares plummeted over 90% after an unexpected trial failure.

What happened

Up until yesterday, shares of Edge Therapeutics (NASDAQ: EDGE) had posted gains of 66% year to date as investors eagerly anticipated the results from a late-stage trial for its lead drug candidate, EG-1962. Today, the biopharma stock plunged 92% -- yes, 92% -- after the company announced it would be discontinuing the trial and laying off employees to preserve cash. 

The company's market cap dropped from $480 million to just $40 million on the news, which is equivalent to a vote of no confidence from investors. Considering that its next most advanced clinical trial is only in phase 1, and is also testing EG-1962, that may be a painfully accurate assessment of Edge Therapeutics' future.

As of 12:37 p.m. EDT, the stock was down 92.1%.

A chart drawn on a chalkboard originally showing gains, but the last half of the chart is poorly erased and redrawn to show a sharp decline.

Image source: Getty Images.

So what

One-day drops of 90% are incredibly rare. In this case, the market was clearly betting that a successful late-stage outcome was the most likely conclusion when top-line data were released in late 2018.

That's because EG-1962 turned in promising data from an earlier phase 1/2 trial for the delivery of the drug used to treat adults with aneurysmal subarachnoid hemorrhage (aSAH). The novel delivery method was expected to greatly decrease the negative side effects associated with traditional treatment methods and become the new standard of care for the brain injury.

But after conducting an interim analysis, the Independent Data Monitoring Committee didn't think continuing the trial would result in EG-1962 meeting its primary endpoint. Management decided to discontinue the trial as a result, which was completely unexpected.

The pipeline won't be bailing out shareholders any time soon. EG-1962 is being investigated in a phase 1 trial and an Investigational New Drug enabling study for treating similar injuries. A second drug candidate, EG-1964, is in preclinical trials. In other words, even if the drug candidates and approach can be proven to work, investors are looking at a very long road ahead. 

Now what

Late-stage trial failures are never welcome news. This stings a bit more for Edge Therapeutics because it was essentially a one-trick pony presenting a high-risk, high-reward investment opportunity.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
673%
 
S&P 500 Returns
142%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.